OBJECT: The aim of this study was to evaluate the role of certain cell-cycle regulatory proteins in the recurrence of atypical meningiomas. These proteins were analyzed with immunohistochemical staining to identify predisposing factors for the recurrence of atypical meningiomas. METHODS: The authors retrospectively reviewed the medical records of patients with atypical meningiomas diagnosed in the period from January 2000 to June 2012 at the Department of Neurosurgery at Samsung Changwon Hospital and Dong-A University Medical Center. Clinical data included patient sex and age at the time of surgery, presenting symptoms at diagnosis, location and size of tumor, extent of surgery, use of postoperative radiotherapy, duration of follow-up, and recurrence. Immunohistochemical staining for cell-cycle regulatory proteins (p16, p15, p21, p27, cyclin-dependent kinase [CDK] 4 and 6, phosphorylated retinoblastoma [pRB] protein, and cyclin D1) and proliferative markers (MIB-1 antigen, mitosis, and p53) was performed on archived paraffin-embedded tissues obtained during resection. The recurrence rate and time to recurrence were assessed using Kaplan-Meier analysis. RESULTS: Of the 67 atypical meningiomas eligible for analysis, 26 (38.8%) recurred during the follow-up period (mean duration 47.7 months, range 8.4-132.1 months). Immunohistochemically, there was overstaining for p16 in 44 samples (65.7%), for p15 in 21 samples (31.3%), for p21 in 25 samples (37.3%), for p27 in 32 samples (47.8%), for CDK4 in 38 samples (56.7%), for CDK6 in 26 samples (38.8%), for pRB protein in 42 samples (62.7%), and for cyclin D1 in 49 samples (73.1%). Multivariate analysis using the Cox proportional-hazards regression model showed that incomplete resection (HR 4.513, p < 0.001); immunohistochemical understaining for p16 (HR 3.214, p < 0.001); immunohistochemical overstaining for CDK6 (HR 3.427, p < 0.001), pRB protein (HR 2.854, p = 0.008), and p53 (HR 2.296, p = 0.040); and increased MIB-1 labeling index (HR 2.665, p = 0.013) and mitotic index (HR 2.438, p = 0.024) predicted the recurrence of atypical meningiomas after resection. CONCLUSIONS: Findings in this study indicated that p16, CDK6, and pRB protein were associated with the recurrence of atypical meningiomas.
OBJECT: The aim of this study was to evaluate the role of certain cell-cycle regulatory proteins in the recurrence of atypical meningiomas. These proteins were analyzed with immunohistochemical staining to identify predisposing factors for the recurrence of atypical meningiomas. METHODS: The authors retrospectively reviewed the medical records of patients with atypical meningiomas diagnosed in the period from January 2000 to June 2012 at the Department of Neurosurgery at Samsung Changwon Hospital and Dong-A University Medical Center. Clinical data included patient sex and age at the time of surgery, presenting symptoms at diagnosis, location and size of tumor, extent of surgery, use of postoperative radiotherapy, duration of follow-up, and recurrence. Immunohistochemical staining for cell-cycle regulatory proteins (p16, p15, p21, p27, cyclin-dependent kinase [CDK] 4 and 6, phosphorylated retinoblastoma [pRB] protein, and cyclin D1) and proliferative markers (MIB-1 antigen, mitosis, and p53) was performed on archived paraffin-embedded tissues obtained during resection. The recurrence rate and time to recurrence were assessed using Kaplan-Meier analysis. RESULTS: Of the 67 atypical meningiomas eligible for analysis, 26 (38.8%) recurred during the follow-up period (mean duration 47.7 months, range 8.4-132.1 months). Immunohistochemically, there was overstaining for p16 in 44 samples (65.7%), for p15 in 21 samples (31.3%), for p21 in 25 samples (37.3%), for p27 in 32 samples (47.8%), for CDK4 in 38 samples (56.7%), for CDK6 in 26 samples (38.8%), for pRB protein in 42 samples (62.7%), and for cyclin D1 in 49 samples (73.1%). Multivariate analysis using the Cox proportional-hazards regression model showed that incomplete resection (HR 4.513, p < 0.001); immunohistochemical understaining for p16 (HR 3.214, p < 0.001); immunohistochemical overstaining for CDK6 (HR 3.427, p < 0.001), pRB protein (HR 2.854, p = 0.008), and p53 (HR 2.296, p = 0.040); and increased MIB-1 labeling index (HR 2.665, p = 0.013) and mitotic index (HR 2.438, p = 0.024) predicted the recurrence of atypical meningiomas after resection. CONCLUSIONS: Findings in this study indicated that p16, CDK6, and pRB protein were associated with the recurrence of atypical meningiomas.
Authors: Yuhao Shi; Saumya R Bollam; Shannon M White; Sean Z Laughlin; Garrett T Graham; Mandheer Wadhwa; Hengye Chen; Chan Nguyen; Jeremie Vitte; Marco Giovannini; Jeffery Toretsky; Chunling Yi Journal: Dev Cell Date: 2016-11-03 Impact factor: 12.270
Authors: Omaditya Khanna; Anahita Fathi Kazerooni; Christopher J Farrell; Michael P Baldassari; Tyler D Alexander; Michael Karsy; Benjamin A Greenberger; Jose A Garcia; Chiharu Sako; James J Evans; Kevin D Judy; David W Andrews; Adam E Flanders; Ashwini D Sharan; Adam P Dicker; Wenyin Shi; Christos Davatzikos Journal: Neurosurgery Date: 2021-10-13 Impact factor: 5.315
Authors: G Trott; J F S Pereira-Lima; C G S Leães; N P Ferreira; L M Barbosa-Coutinho; M C Oliveira Journal: Braz J Med Biol Res Date: 2015-03-03 Impact factor: 2.590
Authors: Sang Hyuk Lee; Eun Hee Lee; Sung-Hun Lee; Young Min Lee; Hyung Dong Kim; Young Zoon Kim Journal: J Korean Med Sci Date: 2015-07-15 Impact factor: 2.153
Authors: B R Ongaratti; C B O Silva; G Trott; T Haag; C G S Leães; N P Ferreira; M C Oliveira; J F S Pereira-Lima Journal: Braz J Med Biol Res Date: 2016-03-18 Impact factor: 2.590